Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05607641
Other study ID # KPF07-T
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date July 7, 2021
Est. completion date May 13, 2022

Study information

Verified date November 2022
Source Darnitsa Pharmaceutical Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Neospastil (ketorolac tromethamine / pitofenone hydrochloride / fenpiverinium bromide fixed-dose combination) in a form of solution for injections and film-coated tablets has been studied as a treatment for pain after surgical abdominal and pelvic operations. The aim of the study was to test the hypothesis that Neospastil was non-inferior (phase II) and superior (phase III) than ketorolac tromethamine monotherapy due to the additional relaxing effect of pitofenone and fenpiverinium on the smooth muscles of internal organs. The study also aimed to show that Neospastil is safe and well-tolerated in people who have pain after surgical abdominal and pelvic operations. Study treatment was initiated with parenteral form of study drug (first 24 hours) and then switched to oral formulation. This trial was conducted in accordance with the ethical principles of Good Clinical Practice and International Council for Harmonization (ICH) Harmonized Tripartite Guidelines.


Recruitment information / eligibility

Status Completed
Enrollment 424
Est. completion date May 13, 2022
Est. primary completion date May 7, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 64 Years
Eligibility Criteria Abbreviations: New York Heart Association (NYHA). Inclusion Criteria: 1. Age of 18-64 years inclusive and body weight of = 50 kg. 2. The estimated need to use the first dose of the IMP no later than 8 hours after the completion of minimally invasive surgical abdominal and pelvic operations. 3. Immediately before randomization, there is a moderate to severe pain associated with minimally invasive surgical abdominal and pelvic operation (the overall assessment of pain at rest is 4-8 points inclusively in 11-point NRS). 4. At the time of minimally invasive surgery, the patient's condition corresponded to the class I-III of general anesthesia risk according to the classification of the American Society of Anesthesiologists (ASA). 5. The patient is able to adequately assess his/her condition and fill in yourself the patient's diary. 6. The patient agrees to participate in the clinical trial and fulfill all the requirements of the trial and has signed the informed consent form. 7. According to the investigator, IMP is an adequate tactic for postoperative analgesia. Exclusion Criteria: 1. Hypersensitivity or allergic reactions/conditions associated with ketorolac, pitofenone, fenpiverinium, any other components of IMPs, acetylsalicylic acid or other non-steroidal anti-inflammatory drugs. 2. The patient has another disease/condition that requires constant use of non-topical analgesics and/or anti-inflammatory agents or, in the opinion of the investigator, disturbs the patient's perception of postoperative pain. 3. The need for postoperative treatment in the intensive care unit for any reason. 4. Active peptic ulcer, recent gastrointestinal bleeding or perforation, history of peptic ulcer or gastrointestinal bleeding. 5. History of bronchial asthma. 6. Severe heart failure (class III-IV according to NYHA). 7. Severe liver failure (including an increase in the activity of alanine aminotransferase and/or aspartate aminotransferase in the blood more than three times the upper limit of normal). 8. Moderate to severe renal failure (blood creatinine concentration > 160 µmol/l). 9. Suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, including blood coagulation disorders and high risk of bleeding. 10. Dehydration with the risk of kidney failure due to a decrease in the volume of circulating blood. 11. Benign prostatic hyperplasia of the ?? and ??? degree. 12. Cardiovascular diseases in which an increase in heart rate may be undesirable (for example, atrial fibrillation, tachycardia [pulse rate at rest > 100 bpm], severe arterial hypertension), as well as an artificial pacemaker. 13. Glaucoma. 14. Signs of intestinal obstruction and/or history of megacolon. 15. Anemia (hemoglobin concentration < 90 g/l) and/or leukopenia (leukocyte count < 3.2x109/l) according to the results of preoperative laboratory examination. 16. Diseases or conditions that make it impossible to take drugs orally in accordance with the Clinical Trial Protocol and/or disrupt their absorption in the gastrointestinal tract. 17. The use of drugs prohibited by the Clinical Trial Protocol before the start of study treatment and/or the need to use drugs prohibited by the Clinical Trial Protocol during the investigational treatment. 18. Mental disorder/illness, which, in the opinion of the investigator, may prevent the patient from fulfilling all the requirements of the trial. 19. Pregnancy or lactation. 20. Within 30 days prior to randomization, the use of a drug or medical product in another clinical trial. 21. The patient has already been previously randomized in this trial. Criteria to start the 2nd stage of treatment, the patient had to meet the criteria for switching to IMP for oral administration: - pain level of 4-6 points at movements according to the 11-point Numerical Rating Scale (NRS) (7 points were allowed, if pain level at rest did not exceed 6 points according to 11-point NRS); - no more than 12 hours have passed since the last use of IMP; - oral analgesic use is an adequate tactic for postoperative analgesia.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ketorolac tromethamine, solution for injection then Neospastil, film-coated tablets
These medicines were used for patients of Group 1 (phase II) and Group 4 (phase III). Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours. Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours. Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.
Ketorolac tromethamine, solution for injection then Ketorolac tromethamine, coated tablets
These medicines were used for patients of Group 2 (phase II) and Group 5 (phase III). Stage 1 (1st day of study treatment) - Ketorolac tromethamine, solution for injection, 1 ml every 8 hours. Stage 2 (2nd day of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet every 6 hours. Stage 3 (3rd-5th days of study treatment) - Ketorolac tromethamine, coated tablets, 1 tablet on demand with an interval of at least 6 hours, not more than 4 tablets per day.
Neospastil, solution for injection then Neospastil, film-coated tablets
These medicines were used for patients of Group 3 (phase II) and Group 6 (phase III). Stage 1 (1st day of study treatment) - Neospastil, solution for injection, 2 ml every 8 hours. Stage 2 (2nd day of study treatment) - Neospastil, film-coated tablets, 1 tablet every 6 hours. Stage 3 (3rd-5th days of study treatment) - Neospastil, film-coated tablets, on demand 1 tablet with an interval of at least 6 hours, not more than 4 tablets per day.

Locations

Country Name City State
Ukraine Regional municipal nonprofitable institution "Chernivtsi regional clinical hospital", urological department Chernivtsi
Ukraine Communal enterprise "Dnipropetrovsk Regional Clinical Hospital named after ?.?. Mechnikov" Dnipropetrovsk Regional Council", urology department ?1 Dnipro
Ukraine Communal enterprise "Dnipropetrovsk Regional Clinical Hospital named after ?.?. Mechnikov" Dnipropetrovsk Regional Council", urology department ?2 Dnipro
Ukraine Communal noncomercial enterprise of the Kharkiv Regional Council "Regional Medical Clinical Center of Urology and Nephrology named after V.I. Shapovala", urology department ?5 Kharkiv
Ukraine Communal noncomercial enterprise "Kyiv City Clinical Hospital #3" Kyiv City Council (Kyiv City State Administration), urological department Kyiv
Ukraine Medical Center of the LLC "Harmony of Beauty" Kyiv
Ukraine State Institution "Institute of Urology of the National Academy of Medical Sciences of Ukraine", I Urological Department Kyiv
Ukraine Communal noncomercial enterprise of the Lviv Regional Council "Lviv Regional Clinical Hospital", department of urology Lviv
Ukraine Municipal Non-profit Enterprise "Lviv Clinical Hospital for Emergency Medical Care" Lviv
Ukraine Communal noncomercial enterprise "City Clinical Hospital #10" Odesa City Council, urological department #2 Odesa
Ukraine Medical-diagnostic center" Zakarpattya center of surgical innovations" Astra-med "of limited liability company" Clinic of healthy family "Astramed" Uzhhorod
Ukraine Communal noncomercial enterprise" Vinnytsia City Clinical Hospital" Mother and Child Center", department of gynecology with minimally invasive operations Vinnytsia
Ukraine Limited Liability Company "Innomed Center of Endosurgery" Vinnytsia
Ukraine Communal noncomercial enterprise "City Hospital of Emergency and Ambulance" of Zaporizhia City Council, Department of Surgery with the Center for Gastrointestinal Bleeding Zaporizhzhya

Sponsors (1)

Lead Sponsor Collaborator
Darnitsa Pharmaceutical Company

Country where clinical trial is conducted

Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of study subjects who achieved a response to treatment within the first 24 hours of using IMP in the form of solution for injections. This primary endpoint was evaluated using the following combined primary (main) efficacy variable.
The patient who met all of the following criteria (1.1-1.3) was considered as a "responder". The patient who didn't meet at least one of the following criteria was classified as a "non-responder".
1.1. Reduction in pain intensity at rest compared to the initial level by = 50 % within the first 90 min. after the first dose of IMP in the form of a solution for injections (i.e., at least at one of the following time points 30 [±5] min., 60 [±10] min. and/or 90 [±15] min.).
1.2. During the study treatment, the intensity of pain at rest is < 4 points on the 11-point NRS at time points between 2 and 24 hours (i.e. 120 [±20] min., 4 [±0.5] h., 6 [±1] h., 8 [±1] h., 16 [±2] h. and 24 [±2] h.) after starting the use of IMP in the form of solution for injections.
1.3. The study subject didn't receive other analgesics during the first 24 hours of the study treatment.
Stage 1 (1st day of treatment).
Primary Proportion of study subjects who achieved a response to treatment within the first 24 hours of using IMP in the form of tablets. This primary endpoint was evaluated using the following combined primary (main) efficacy variable.
The patient who met all of the following criteria (2.1-2.3) was considered as a "responder". The patient who didn't meet at least one of the following criteria was classified as a "non-responder".
2.1. Reduction in pain intensity at movements compared to the initial level by = 50 % within the first 120 min. after the first dose of IMP in the form of tablets (i.e., at least at one of the following time points 60 [±10 min., 90 [±15] min. and/or 120 [±20] min.).
2.2. During the study treatment, the intensity of pain during movement is < 4 points on the 11-point NRS at time points between 3 and 24 hours (i.e. 3 [±0.5] h, 4 [±0.5] h, 6 [±1] h, 12 [±2] h, 18 [±2] h and 24 [±2] h) after starting to use IMP in the form of tablets.
2.3. The study subject didn't receive other analgesics within 24 hours since beginning of the IMP usage in the form of tablets.
Stage 2 (2nd day of treatment).
Secondary Time to a noticeable and distinct decrease in the intensity of pain at rest from the first dose of IMP in the form of a solution for injections. Stage 1 (1st day of treatment)
Secondary Pain intensity at rest and during movements according to the 11-point NRS at time points during the study treatment. Stage 1 (1st day of treatment), Stage 2 (2nd day of treatment) and Stage 3 (3rd-5th days of treatment)
Secondary Area under the curve of pain intensity at rest and during movements according to the 11-point NRS at time points within 24 hours after the first dose of IMP in the form of solution for injections and IMP in the form of tablets. Stage 1 (1st day of treatment) and Stage 2 (2nd day of treatment)
Secondary Sum of pain intensity differences (SPID) at rest and during movements within 6 hours after the first dose of IMP in the form of solution for injections or IMP in the form of tablets. First 6 hours of Stage 1 (1st day of treatment) and Stage 2 (2nd day of treatment)
Secondary The proportion of patients who achieved a response to treatment. A response to treatment based on the patient's overall assessment of pain control within 24 hours using of IMP in the form of a solution for injections and IMP in the form of tablets, as well as at the end of the study treatment. Stage 1 (1st day of treatment), Stage 2 (2nd day of treatment) and Stage 3 (3rd-5th days of treatment)
Secondary The number of IMP doses administered during 3-5 days of the study treatment (per patient). Stage 3 (3rd-5th day of treatment)
Secondary Proportion of patients who used another analgesic since the first dose of IMP. Stage 1 (1st day of treatment), Stage 2 (2nd day of treatment) and Stage 3 (3rd-5th days of treatment)
See also
  Status Clinical Trial Phase
Completed NCT04774328 - Preliminary Study of CA-008 (Vocacapsaicin) in Patients Undergoing Ventral Hernia Repair Phase 1/Phase 2
Completed NCT03731364 - Study of CA-008 (Vocacapsaicin) in Total Knee Arthroplasty Phase 2
Recruiting NCT05193227 - Sustained Release Lidocaine for the Treatment of Postoperative Pain Phase 2
Completed NCT01562483 - The Analgesic Efficacy of Δ9-THC (Namisol®) in Patients With Persistent Postsurgical Abdominal Pain Phase 2
Completed NCT02081703 - Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery Phase 2
Recruiting NCT04647435 - Efficacy and Safety of APSCTC for the Treatment of Postsurgical Pain Due to Third Molar Extraction Phase 3
Completed NCT01582477 - TAP-patients With Robotic Assisted Lap Prostatectomy Phase 4
Suspended NCT04681027 - Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children Phase 3
Not yet recruiting NCT06202989 - Multiprofen-CC™ to Reduce Pain After Total Knee Arthroplasty Phase 3
Completed NCT01731730 - Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery Phase 2
Recruiting NCT05698914 - Telehealth Mindfulness After Spine Surgery N/A
Completed NCT04203537 - Study Evaluating the Safety, Efficacy and Pharmacokinetics of CA-008 (Vocacapsaicin) Phase 1/Phase 2
Completed NCT03789318 - Study in Subjects Undergoing Complete Abdominoplasty Phase 2
Completed NCT04648683 - Postoperative Telehealth Mindfulness Intervention After Spine Surgery N/A
Completed NCT06412380 - Influence of Insertion Torque and Bone Type on Post-operative Pain N/A
Recruiting NCT05394402 - A Trial of SHR0410 Injection in Postsurgical Pain Management Phase 2
Not yet recruiting NCT06344169 - Dinalbuphine Ester (Naldebain) for Pain Management After Cesarean Section Phase 2/Phase 3